Literature DB >> 2324114

Purification of eukaryotic RNA polymerase II by immunoaffinity chromatography. Elution of active enzyme with protein stabilizing agents from a polyol-responsive monoclonal antibody.

N E Thompson1, D B Aronson, R R Burgess.   

Abstract

Active eukaryotic RNA polymerase II (RNAP II) was purified by immunoaffinity chromatography, using a monoclonal antibody (mAb) that reacts with the highly conserved heptapeptide repeat of the largest subunit. This mAb (designated SWG16) was conjugated to CNBr-activated Sepharose and used to purify RNAP II from wheat germ and calf thymus. The subunit composition of the immunoaffinity-purified enzyme was essentially the same as RNAP II purified by conventional chromatography except that it contained only the form with the unproteolyzed largest subunit. Active enzyme could be eluted from the SWG16-Sepharose, at pH 7.9, with combinations of low molecular weight polyols and nonchaotropic salts. The superior eluting procedure used combinations of ethylene glycol (30-40%) and ammonium sulfate (0.5-0.75 M). Active enzyme also could be eluted with a synthetic peptide containing four repeats of the heptapeptide; however, the peptide was not as effective as the polyol and salt combinations for eluting the enzyme. This mAb should be useful for purifying RNAP II from many eukaryotic species. Because the elution of enzyme from the immunoadsorbent seems to be dependent upon the presence of a polyol, this antibody is referred to as a "polyol-responsive mAb." A procedure that helps to identify a polyol-responsive mAb and to optimize the eluting conditions is described. Polyol-responsive mAbs might have broad applicability to the purification of many labile enzymes by immunoaffinity chromatography.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2324114

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

1.  Corepressor required for adenovirus E1B 55,000-molecular-weight protein repression of basal transcription.

Authors:  M E Martin; A J Berk
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

2.  RNA polymerase II holoenzyme modifications accompany transcription reprogramming in herpes simplex virus type 1-infected cells.

Authors:  H L Jenkins; C A Spencer
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Opposing effects of Ctk1 kinase and Fcp1 phosphatase at Ser 2 of the RNA polymerase II C-terminal domain.

Authors:  E J Cho; M S Kobor; M Kim; J Greenblatt; S Buratowski
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

4.  Genetic evidence for selective degradation of RNA polymerase subunits by the 20S proteasome in Saccharomyces cerevisiae.

Authors:  S Nouraini; D Xu; S Nelson; M Lee; J D Friesen
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

5.  Regulation of CDK7 substrate specificity by MAT1 and TFIIH.

Authors:  K Y Yankulov; D L Bentley
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

6.  Subnuclear localization of Ku protein: functional association with RNA polymerase II elongation sites.

Authors:  Xianming Mo; William S Dynan
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

7.  A carboxyl-terminal-domain kinase associated with RNA polymerase II transcription factor delta from rat liver.

Authors:  H Serizawa; R C Conaway; J W Conaway
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Loss of the Rpb4/Rpb7 subcomplex in a mutant form of the Rpb6 subunit shared by RNA polymerases I, II, and III.

Authors:  Qian Tan; Meredith H Prysak; Nancy A Woychik
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

9.  RNA polymerase II carboxy-terminal domain phosphorylation is required for cotranscriptional pre-mRNA splicing and 3'-end formation.

Authors:  Gregory Bird; Diego A R Zorio; David L Bentley
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

10.  Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera.

Authors:  M Satoh; A K Ajmani; T Ogasawara; J J Langdon; M Hirakata; J Wang; W H Reeves
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.